Swiss Life Asset Management Ltd Has $10.16 Million Stock Position in Axon Enterprise, Inc $AXON

Swiss Life Asset Management Ltd grew its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 23.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 14,153 shares of the biotechnology company’s stock after acquiring an additional 2,694 shares during the period. Swiss Life Asset Management Ltd’s holdings in Axon Enterprise were worth $10,157,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. NEOS Investment Management LLC lifted its holdings in shares of Axon Enterprise by 82.7% during the third quarter. NEOS Investment Management LLC now owns 25,369 shares of the biotechnology company’s stock worth $18,206,000 after buying an additional 11,482 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Axon Enterprise by 4.2% in the third quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock valued at $6,684,217,000 after acquiring an additional 376,904 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Axon Enterprise by 3.3% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 184,423 shares of the biotechnology company’s stock valued at $132,349,000 after acquiring an additional 5,953 shares in the last quarter. BIT Capital GmbH increased its position in Axon Enterprise by 75.6% during the third quarter. BIT Capital GmbH now owns 3,535 shares of the biotechnology company’s stock worth $2,537,000 after acquiring an additional 1,522 shares during the period. Finally, Legal & General Group Plc increased its position in Axon Enterprise by 3.1% during the third quarter. Legal & General Group Plc now owns 421,114 shares of the biotechnology company’s stock worth $302,208,000 after acquiring an additional 12,736 shares during the period. Institutional investors own 79.08% of the company’s stock.

Insider Activity

In other Axon Enterprise news, CAO Jennifer H. Mak sold 1,500 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $573.45, for a total value of $860,175.00. Following the sale, the chief accounting officer owned 12,240 shares of the company’s stock, valued at approximately $7,019,028. This trade represents a 10.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Erika Nardini sold 198 shares of Axon Enterprise stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $506.58, for a total value of $100,302.84. Following the completion of the transaction, the director owned 1,946 shares in the company, valued at approximately $985,804.68. The trade was a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 23,855 shares of company stock valued at $13,299,928. Corporate insiders own 4.40% of the company’s stock.

Axon Enterprise Price Performance

AXON stock opened at $496.12 on Friday. The company’s 50-day moving average price is $519.47 and its two-hundred day moving average price is $601.32. The firm has a market cap of $39.89 billion, a P/E ratio of 326.39, a P/E/G ratio of 10.72 and a beta of 1.46. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53. Axon Enterprise, Inc has a 12 month low of $396.41 and a 12 month high of $885.91.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The company had revenue of $796.72 million during the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a net margin of 4.48% and a return on equity of 2.82%. The firm’s quarterly revenue was up 38.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.08 EPS. On average, analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Axon Enterprise News Roundup

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Strong Software & Services momentum supports a higher-margin recurring revenue outlook—analyst write-ups highlight ~38% revenue growth and continued subscription expansion, which underpins long-term upside. Read More.
• Positive Sentiment: Earnings beat: Axon’s Feb. quarter topped estimates on EPS and revenue (revenue up ~38.5% YoY), reinforcing the growth narrative that many investors cite when valuing the stock. Read More.
• Positive Sentiment: Municipal procurement continues to drive hardware + software adoption—local grants (e.g., Decatur, IL) are cited as examples of steady demand for public-safety tech. Read More.
• Positive Sentiment: Institutional/coverage interest (features mentioning funds and “trending” status) can attract flows and boost liquidity, supporting the stock over time. Read More.
• Neutral Sentiment: Aggregator/“trending” articles raise awareness but are not direct fundamental catalysts; useful for retail/institutional interest but don’t change cash flows immediately. Read More.
• Neutral Sentiment: Short-interest data being reported as “0 shares” with NaN changes reads like a reporting error—treat as noise until exchanges/brokers clarify; not an actionable signal now.
• Negative Sentiment: Insider selling: Director Erika Nardini sold 198 shares (~$506.58 avg) and Director Jeri Williams sold 157 shares (~$490 avg) in mid‑March; while small in absolute dollars, these filings can dent sentiment. Read More. Read More.
• Negative Sentiment: Near-term skepticism: critical pieces noting a multi‑day losing streak and a sizable short-term market‑cap decline are amplifying caution and likely contributing to today’s pullback. Read More.

Analyst Upgrades and Downgrades

AXON has been the subject of a number of recent research reports. Barclays cut their price objective on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating for the company in a report on Wednesday, February 25th. UBS Group lowered their target price on shares of Axon Enterprise from $610.00 to $570.00 and set a “neutral” rating on the stock in a report on Wednesday, February 25th. Morgan Stanley dropped their price target on shares of Axon Enterprise from $713.00 to $675.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Royal Bank Of Canada cut their price target on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research note on Wednesday, February 25th. Finally, Craig Hallum reissued a “buy” rating and set a $820.00 price target on shares of Axon Enterprise in a research report on Wednesday, February 25th. Sixteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $762.93.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.